12 Aug 2025
14m
Maze Therapeutics, which had its IPO earlier this year, is using insights from genetics to develop small molecules - its most advanced program is for a genetic kidney disease
BiotechTV - News
Open in Podwise to generate AI notes
Sign in to process this episode and unlock summaries, transcripts, highlights and translations.
Shownotes are not generated by Podwise.